



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

July 31, 2020

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended June 30, 2020

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2020 which were approved by the Board of Directors of the Company, at its meeting held on July 31, 2020 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 03:00 p.m. and concluded at 05:30 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: as above

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on unaudited quarterly financial results under regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

The Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 June 2020 ('the statement').
2. This Statement, which is the responsibility of the Company's management and which is approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Limited Review report on unaudited quarterly financial results under regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W- 100022

HIMANSHU
LALITKUMAR
CHAPSEY

Digitally signed by
HIMANSHU
LALITKUMAR CHAPSEY
Date: 2020.07.31
15:42:22 +05'30'

Himanshu Chapsey
Partner

Membership No: 105731

UDIN: 20105731AAAAEI8516

Place: Mumbai
Date: 31 July 2020

Statement of Financial Results for the quarter ended 30th June 2020

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended
	30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	9,165	8,867	9,404	37,557
2 Other Income	45	38	16	73
3 Total Income	9,210	8,905	9,420	37,630
4 Expenses				
(a) Cost of Materials Consumed	1,914	1,817	1,677	7,513
(b) Purchases of Stock-in-Trade	1,505	927	1,134	5,861
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(492)	308	462	(598)
(d) Employee Benefits Expense	2,400	2,368	2,312	9,590
(e) Finance Costs	31	30	73	175
(f) Depreciation and Amortisation Expense	416	412	392	1,636
(g) Other Expenses	2,153	2,197	2,284	9,276
Total Expenses	7,927	8,059	8,334	33,453
5 Profit before exceptional items and tax	1,283	846	1,086	4,177
6 Exceptional Items Gain/(Loss) (See Note 4)	-	(532)	-	(532)
7 Profit before tax	1,283	314	1,086	3,645
8 Income tax expenses				
a. Current Tax	411	62	300	1,010
b. Deferred Tax	(34)	(46)	(49)	(266)
9 Profit for the period	906	298	835	2,901
10 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(6)	6	(10)	(24)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	(1)	3	7
Other Comprehensive Income Net of Tax	(4)	5	(7)	(17)
11 Total Comprehensive Income for the period	902	303	828	2,884
12 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
13 Other Equity				16,334
14 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):				
(a) Basic	5.48	1.80	5.05	17.54
(b) Diluted	5.48	1.80	5.05	17.54

.. 2 ..

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2020.
- 2 Figures for the quarter ended March 31, 2020 are the balancing figures between the audited financial results for the year ended March 31, 2020 and the published unaudited financial results for the nine months ended December 31, 2019 which were subjected to a limited review.
- 3 The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- 4 Exceptional items for the year ended March 31, 2020 relates to write off of an intangible asset under development. The Company does not expect any future economic benefits to flow to the Company hence the cost incurred till date have been charged off during the quarter ended March 31, 2020.
- 5 In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. As indicated in the notes to the results for the quarter ended March 31, 2020, the Company continues to monitor the situation and has adopted stringent measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption.

The Company has considered internal and external information while finalizing various estimates in relation to its financial results upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID-19 situation evolves in India and globally. The Company continues to track any material changes to expected future economic conditions.

For RPG Life Sciences Limited



Yugal Sikri
Managing Director
Mumbai, July 31, 2020